Trial
NCT03474263
IC14 for Rapidly Progressive Amyotrophic Lateral Sclerosis (ALS)
Phase IIWITHDRAWNOPERATIONALConfidence: HIGH
Sponsor
Implicit Bioscience
Collaborators
—
Condition
Amyotrophic Lateral Sclerosis
Intervention
Biologic: IC14 (monoclonal antibody against human CD14)
Why stopped
No enrollment
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2026-05-05